|Articles|January 8, 2019

Turnover Within CRO Companies Remains Persistently High

CRO companies are battling high turnover levels, but a new report from BDO USA, LLP, finds that compensation strategies generally have not made enough adjustments to their compensation strategy to address this on going issue. This report examines compensation and benefits trends in the CRO industry over the last 10 years, with a special focus on clinical research associates.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Turnover Within CRO Companies Remains Persistently High

Newsletter

Related Content

After the Trial is too Late: The Case for More Active Use of Patient-Reported Outcomes in Oncology Studies

Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor

Setting the Limits of Autonomy with Autonomous Agents for Clinical Research

Retention by Design: Operationalizing Patient-Centric Trials Without Increasing Site Burden

Streamlining Trial Design to Accelerate Data Delivery and Investor Confidence

Trending on Applied Clinical Trials Online

Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor

Future-Proofing Clinical Trial Supply Chains Against Tariff Risks

Eli Lilly’s Orforglipron Shows Superior Efficacy Across Multiple Phase III Trials in Type 2 Diabetes

Labels That Withstand Liquid Nitrogen

Setting the Limits of Autonomy with Autonomous Agents for Clinical Research